ANDA 210213, held by Msn Labs Pvt Ltd. Alogliptin Benzoate.
As of Nov 15, 2026, ANDA 210213 (Alogliptin), held by Msn Labs Pvt Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2019 | Original application | Tentative approval |
| AlogliptinEQ 6.25MG BASE · tablet;oral | Alogliptin Benzoate | None (tentative approval) |
| AlogliptinEQ 12.5MG BASE · tablet;oral | Alogliptin Benzoate | None (tentative approval) |
| AlogliptinEQ 25MG BASE · tablet;oral | Alogliptin Benzoate | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
